Recent Research Analysts’ Ratings Updates for Merit Medical Systems (MMSI)

Posted by Jeff Wilder on Jan 31st, 2025

Merit Medical Systems (NASDAQ: MMSI) recently received a number of ratings updates from brokerages and research firms:

1/29/2025 – Merit Medical Systems had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $116.00 price target on the stock, up previously from $114.00.
1/29/2025 – Merit Medical Systems had its price target raised by analysts at Barrington Research from $114.00 to $115.00. They now have an “outperform” rating on the stock.
1/29/2025 – Merit Medical Systems had its price target raised by analysts at Needham & Company LLC from $109.00 to $122.00. They now have a “buy” rating on the stock.
1/29/2025 – Merit Medical Systems had its price target raised by analysts at Canaccord Genuity Group Inc. from $127.00 to $128.00. They now have a “buy” rating on the stock.
1/21/2025 – Merit Medical Systems had its price target raised by analysts at Piper Sandler from $110.00 to $114.00. They now have an “overweight” rating on the stock.
1/14/2025 – Merit Medical Systems had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $109.00 price target on the stock.
12/31/2024 – Merit Medical Systems had its price target raised by analysts at Raymond James from $105.00 to $110.00. They now have an “outperform” rating on the stock.
12/23/2024 – Merit Medical Systems had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $114.00 price target on the stock.
12/11/2024 – Merit Medical Systems was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $120.00 price target on the stock, up previously from $103.00.
12/9/2024 – Merit Medical Systems had its price target raised by analysts at Canaccord Genuity Group Inc. from $125.00 to $127.00. They now have a “buy” rating on the stock.

Merit Medical Systems Stock Up 1.7 %

MMSI stock opened at $110.29 on Friday. Merit Medical Systems, Inc. has a 1-year low of $70.70 and a 1-year high of $111.27. The stock has a market cap of $6.43 billion, a P/E ratio of 54.06, a P/E/G ratio of 2.42 and a beta of 0.85. The stock’s fifty day simple moving average is $101.36 and its two-hundred day simple moving average is $97.04. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. The company had revenue of $339.85 million during the quarter, compared to analyst estimates of $334.60 million. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 earnings per share. Analysts expect that Merit Medical Systems, Inc. will post 3.37 EPS for the current year.

Insider Activity

In related news, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the completion of the sale, the director now owns 32,391 shares of the company’s stock, valued at approximately $3,289,306.05. This trade represents a 27.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the completion of the sale, the chief financial officer now owns 16,361 shares in the company, valued at $1,603,705.22. This represents a 64.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. American Century Companies Inc. raised its stake in shares of Merit Medical Systems by 2.9% during the 2nd quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 118 shares during the period. Squarepoint Ops LLC grew its holdings in Merit Medical Systems by 170.7% during the 2nd quarter. Squarepoint Ops LLC now owns 26,665 shares of the medical instruments supplier’s stock valued at $2,292,000 after buying an additional 64,401 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Merit Medical Systems by 36.1% during the second quarter. AQR Capital Management LLC now owns 11,043 shares of the medical instruments supplier’s stock valued at $949,000 after buying an additional 2,931 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Merit Medical Systems in the second quarter worth about $756,000. Finally, Creative Planning boosted its position in shares of Merit Medical Systems by 34.9% in the second quarter. Creative Planning now owns 15,020 shares of the medical instruments supplier’s stock valued at $1,291,000 after acquiring an additional 3,887 shares during the period. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.